Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Prepares For US Sirukumab Launch After Regaining Rights From GSK

Executive Summary

GSK returned US rights to the IL-6 blocker to J&J as it prioritizes its pharma portfolio under the leadership of new CEO Walmsley.

Advertisement

Related Content

EU Confirms Sirukumab Filing Withdrawal, J&J Moves On
J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback
Janssen's Sirukumab Faces Difficult US Commercial Path Even If It Clears Approval Hurdles
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market
Sanofi/Regeneron's Kevzara Priced To Break Into A Crowded Market
J&J Forges Ahead In Immunology Despite Competitive Dynamics
GSK's Immunology Strategy Edges Closer To Delivering
GSK’s Tanzeum Launch Marks The Big Pharma’s Return To Diabetes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099210

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel